Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
about
Genomic mutation-driven metastatic breast cancer therapy: a single center experienceSpecific inhibition of p110α subunit of PI3K: putative therapeutic strategy for KRAS mutant colorectal cancersInhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.Breast cancer suppression by aplysin is associated with inhibition of PI3K/AKT/FOXO3a pathway.Up-regulation of miR-497 confers resistance to temozolomide in human glioma cells by targeting mTOR/Bcl-2.IGF1R upregulation confers resistance to isoform-specific inhibitors of PI3K in PIK3CA-driven ovarian cancer
P2860
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@ast
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@en
type
label
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@ast
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@en
prefLabel
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@ast
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition.
@en
P2093
P2860
P1476
Activation of IGF1R/p110β/AKT/mTOR confers resistance to α-specific PI3K inhibition
@en
P2093
Cedric Leroy
Christine Fritsch
Debora Bonenfant
Hans Voshol
Karen Cornille
Pedro Ramos
P2860
P2888
P356
10.1186/S13058-016-0697-1
P577
2016-04-05T00:00:00Z
P6179
1027572970